A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

To join this study, you generally need to be an adult aged 18 to 65 years old and have been diagnosed with rheumatoid arthritis for at least three months. It's important that you are currently taking one or two standard rheumatoid arthritis medications (DMARDs) and have been on a steady dose of these for at least eight weeks before the study begins. You should also have found that at least one of your previous rheumatoid arthritis medications hasn't worked well enough for you, or you haven't been able to tolerate it.

There are also some reasons why you might not be able to join. For example, if you have other inflammatory joint diseases, or if you've had certain types of cancer in the last five years, you wouldn't be eligible. The study also can't include people who have a weakened immune system, or if you are pregnant or breastfeeding. If you've previously taken certain immune-system-affecting drugs, this would also prevent you from joining.

If you decide to take part, you'll be randomly assigned to either receive Rosnilimab or a placebo (a dummy drug). This means neither you nor your study doctor will know which treatment you are receiving. You will need to attend regular appointments at the clinic over a period of time. These visits will involve various health checks, blood tests, and discussions about how you are feeling and any symptoms you are experiencing. You will also be given the study medication to take as instructed. The total duration of your participation in the study, including all follow-up, will be explained in detail by the study team.